Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | PRKDC | P78527 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3645769 | 0.89 | ALDH1A1 (0.59) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL13252228 | 0.87 | ALDH1A1 (0.51) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL16687494 | 0.87 | ALDH1A1 (0.51) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL4043187 | 0.87 | ALDH1A1 (0.57) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL27173131 | 0.87 | ALDH1A1 (0.54) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL40798 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL66837 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL5058658 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL1261460 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL12978933 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400166-A2 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| EP-3565484-B1 | COMPOSITIONS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | CONTRALINE INC (US) | 2024-04-03 | — | — | EP | claimed |
| US-11891668-B2 | Methods for generating therapeutic delivery platforms | THE UNIVERSITY OF KANSAS (US) | 2024-02-06 | — | — | US | claimed |
| US-20180185096-A1 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. | 2018-07-05 | — | — | US | claimed |
| US-20160138092-A1 | PHOTOBLOCKED PROBES AND METHODS FOR SEQUENTIAL DETECTION OF NUCLEIC ACIDS | ROCHE MOLECULAR SYSTEMS, INC. | 2016-05-19 | — | — | US | claimed |
| US-20100075297-A1 | PHOTOSENSITIVE POLYPEPTIDE AND METHODS OF THEIR PRODUCTION AND USE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-03-25 | — | — | US | claimed |
| US-7544736-B2 | Methods of preparing latex particulates with reactive functional groups | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2009-06-09 | — | — | US | claimed |
| US-7291514-B2 | Bottom electrode chemically-bonded Langmuir-Blodgett films via photolabile groups | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2007-11-06 | — | — | US | claimed |
| US-7175961-B2 | Photopatternable molecular circuitry | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2007-02-13 | — | — | US | claimed |
| US-7144683-B2 | Photopatternable molecular circuitry | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2006-12-05 | — | — | US | claimed |
| US-6995206-B2 | Methods of preparing latex particulates with reactive functional groups | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2006-02-07 | — | — | US | claimed |
| WO-2005087798-A1 | D-SER!8-CYCLOSPORINE MODIFIED ON THE HYDROXYL GROUP HAVING A SWITCHABLE INHIBITING EFFECT ON PROTEIN PHOSPHATASE CALCINEURINE AND SPECIFIC MANIPULIPULATABILITY OBTAINED THEREWITH OF THE IMMUNOSUPPRESSIVE EFFECT WHILE MAINTAINING INHIBITION OF PEPTIDYL-PROLYL-CIS-TRANS-ISOMERASE (PPI) E.G. FOR THE TREATMENT OF AUTOIMMUNE D | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2005-09-22 | — | — | WO | claimed |
| US-20050194526-A1 | Bottom electrode chemically-bonded Langmuir-Blodgett films via photolabile groups | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2005-09-08 | — | — | US | claimed |
| US-20050027065-A1 | Methods and preparing latex particulates with reactive functional groups | HEWLETT-PACKARD DEVELOPMENT COMPANY L.P. | 2005-02-03 | — | — | US | claimed |
| EP-1502929-A1 | Methods of preparing latex particulates with reactive functional groups | Hewlett-Packard Development Company, L.P. (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040122233-A1 | Photopatternable molecular circuitry | BECK PATRICIA A (US) | 2004-06-24 | — | — | US | claimed |
| US-20030194630-A1 | Photopatternable molecular circuitry | HEWLETT-PACKARD DEVELOPMENT COMPANY L.P. | 2003-10-16 | — | — | US | claimed |
| US-20010046676-A1 | Integrated sequencing device | BBI BIOSEQ, INC., MASSACHUSETTS CORPORATION | 2001-11-29 | — | — | US | claimed |
| US-6245506-B1 | IMMOBILIZING BIOPOLYMER ON SOLID SUPPORT IN REACTION VESSEL, MIXING WITH ION DEPENDENT ENZYME AND PRESSURE SENSITIVE BUFFER, ALTERING PRESSURE IN THE VESSEL TO ALLOW REACTION TO OCCUR, DETERMINING IDENTITY OF DISSOCIATED TERMINAL MONOMER | BBI BIOSEQ, INC. | 2001-06-12 | — | — | US | claimed |
| US-6020480-A | Caged NADP and NAD | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-02-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075297-A1 | PHOTOSENSITIVE POLYPEPTIDE AND METHODS OF THEIR PRODUCTION AND USE | NPEPPS, DNPEP, ANPEP | ALDH1A1 3439/4885CYP2D6 3352/4885L3MBTL1 3218/4885 |
| US-11891668-B2 | Methods for generating therapeutic delivery platforms | EXOSC4, EXOSC5, EXOSC9 | ALDH1A1 2893/4885CYP2D6 4496/4885L3MBTL1 888/4885 |
| US-20040122233-A1 | Photopatternable molecular circuitry | CDH1, VIM, CAT | ALDH1A1 893/4885CYP2D6 3591/4885L3MBTL1 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.